There is growing legislative support for the development of the pharmaceutical and vaccine industry based on the BCG concept. The list below summarizes the actions that will be taken.
1. To modify funding for research and development at all stages to multi-year and block grants by supporting public-private investment cooperation and using intellectual property legally;
2. To adjust the vaccine procurement mechanism and biomaterials from annual to multi-year procurement, as well as taking additional supportive measures for the procurement of products or innovations produced in the country;
3. To prepare national guidelines issued by the government to provide advice on development, production, and registration, with contact channels for advice from FDA 33;
4. To improve special privileges, such as conditions for soft loans, by relaxing loan conditions and repayment periods, as well as extending the period of corporate income tax exemption privileges appropriately and seeking funding sources in the initial stage before the distribution starts;
5. To establish market creation mechanisms (public sector) and incentives to support products manufactured or researched and developed in the country, in order to compete in terms of price with products abroad (such as giving product support for locally produced vaccines and biologics added to the Innovation List to expand government markets, pushing vaccines into the EPI program/ List of Essential Medicine, or using different special consideration criteria to create privileges for domestically produced products);
6. To unlock the law to build foreign confidence in research investment, development and industry (GMOs, Bay Dole Act, etc.);
7. To establish strict laws to control exaggerated advertising, along with creating better public awareness.
Source: National Science and Technology Development Agency (NSTDA)
Tel:+66 (0) 2-564-7000
EN
CN
DE
JP
TH
